Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Palliative Care | 6 | 2004 | 271 | 0.650 |
Why?
|
| Terminal Care | 7 | 2004 | 92 | 0.570 |
Why?
|
| Neoplasms | 11 | 2005 | 1660 | 0.540 |
Why?
|
| Medical Oncology | 2 | 2004 | 110 | 0.450 |
Why?
|
| Physician's Role | 2 | 2004 | 116 | 0.320 |
Why?
|
| Pain | 4 | 2004 | 472 | 0.300 |
Why?
|
| Ethics, Medical | 3 | 2003 | 86 | 0.260 |
Why?
|
| Physician-Patient Relations | 2 | 2004 | 261 | 0.260 |
Why?
|
| Double Effect Principle | 1 | 2003 | 1 | 0.240 |
Why?
|
| Death | 1 | 2004 | 38 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 2 | 2004 | 332 | 0.220 |
Why?
|
| Attitude to Death | 4 | 2004 | 52 | 0.210 |
Why?
|
| Euthanasia | 2 | 1991 | 14 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 467 | 0.200 |
Why?
|
| Withholding Treatment | 2 | 1991 | 35 | 0.180 |
Why?
|
| Philosophy, Medical | 3 | 2003 | 12 | 0.170 |
Why?
|
| Pain, Intractable | 2 | 1990 | 28 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 1533 | 0.130 |
Why?
|
| Hospice Care | 1 | 1995 | 29 | 0.130 |
Why?
|
| Pain Measurement | 1 | 1995 | 328 | 0.120 |
Why?
|
| Terminally Ill | 2 | 2005 | 17 | 0.120 |
Why?
|
| Cancer Care Facilities | 2 | 1990 | 32 | 0.110 |
Why?
|
| Humans | 24 | 2021 | 68525 | 0.100 |
Why?
|
| Euthanasia, Passive | 1 | 1991 | 3 | 0.100 |
Why?
|
| Euthanasia, Active | 1 | 1991 | 3 | 0.100 |
Why?
|
| Euthanasia, Active, Voluntary | 1 | 1991 | 7 | 0.100 |
Why?
|
| Hospitals, Special | 1 | 1990 | 15 | 0.100 |
Why?
|
| Goals | 1 | 1990 | 65 | 0.090 |
Why?
|
| Beds | 1 | 1990 | 13 | 0.090 |
Why?
|
| Melanoma | 2 | 2005 | 335 | 0.090 |
Why?
|
| Adjustment Disorders | 2 | 2005 | 9 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 88 | 0.070 |
Why?
|
| Aged | 9 | 2021 | 14842 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2007 | 140 | 0.070 |
Why?
|
| Brain Neoplasms | 2 | 1988 | 371 | 0.070 |
Why?
|
| Morphine | 1 | 1987 | 76 | 0.070 |
Why?
|
| Prognosis | 3 | 2005 | 2093 | 0.070 |
Why?
|
| Cancer Vaccines | 2 | 2005 | 61 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 1985 | 83 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 1991 | 824 | 0.060 |
Why?
|
| Remote Consultation | 1 | 2005 | 50 | 0.060 |
Why?
|
| Intestinal Obstruction | 1 | 2004 | 36 | 0.060 |
Why?
|
| Patients | 1 | 2004 | 69 | 0.060 |
Why?
|
| Cholestasis | 1 | 2004 | 90 | 0.060 |
Why?
|
| Hospices | 2 | 1995 | 14 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2005 | 311 | 0.060 |
Why?
|
| Fatigue | 1 | 2004 | 132 | 0.060 |
Why?
|
| AIDS Vaccines | 1 | 2002 | 7 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2002 | 19 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 799 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2005 | 253 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 10 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 191 | 0.050 |
Why?
|
| Middle Aged | 8 | 2021 | 21119 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 560 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4843 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2002 | 149 | 0.050 |
Why?
|
| Home Care Services | 2 | 1995 | 84 | 0.050 |
Why?
|
| Adult | 7 | 2021 | 21375 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2005 | 438 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 265 | 0.050 |
Why?
|
| Caregivers | 1 | 2004 | 365 | 0.050 |
Why?
|
| Physicians | 1 | 2004 | 324 | 0.050 |
Why?
|
| Decision Making | 1 | 2003 | 410 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2005 | 561 | 0.040 |
Why?
|
| Empathy | 2 | 1991 | 45 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2005 | 2798 | 0.040 |
Why?
|
| Depression | 1 | 2004 | 942 | 0.040 |
Why?
|
| Female | 7 | 2021 | 38015 | 0.030 |
Why?
|
| HIV Infections | 1 | 2002 | 775 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3702 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 1995 | 342 | 0.030 |
Why?
|
| Ethics | 1 | 1991 | 17 | 0.030 |
Why?
|
| Morals | 1 | 1991 | 27 | 0.020 |
Why?
|
| Homicide | 1 | 1991 | 59 | 0.020 |
Why?
|
| Intention | 1 | 1991 | 78 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 1991 | 100 | 0.020 |
Why?
|
| Air | 1 | 1990 | 22 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 219 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 1990 | 319 | 0.020 |
Why?
|
| Equipment Design | 1 | 1990 | 500 | 0.020 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1988 | 6 | 0.020 |
Why?
|
| Male | 5 | 2007 | 37281 | 0.020 |
Why?
|
| Life Support Care | 1 | 1988 | 12 | 0.020 |
Why?
|
| Uncertainty | 1 | 1988 | 31 | 0.020 |
Why?
|
| Survival Rate | 1 | 1990 | 1055 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2007 | 35 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 96 | 0.020 |
Why?
|
| Trust | 1 | 1988 | 75 | 0.020 |
Why?
|
| Motivation | 1 | 1991 | 561 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 216 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 238 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 1987 | 120 | 0.020 |
Why?
|
| Prevalence | 1 | 1990 | 1609 | 0.020 |
Why?
|
| Neurocognitive Disorders | 1 | 1985 | 23 | 0.020 |
Why?
|
| Nausea | 1 | 1985 | 47 | 0.020 |
Why?
|
| Vomiting | 1 | 1985 | 56 | 0.020 |
Why?
|
| Inpatients | 1 | 1987 | 208 | 0.020 |
Why?
|
| Drug Utilization | 1 | 1985 | 119 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2005 | 66 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 53 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 125 | 0.020 |
Why?
|
| Professional-Patient Relations | 1 | 2005 | 71 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2005 | 133 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 1985 | 91 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2003 | 36 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2003 | 28 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 251 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1745 | 0.010 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Gene Products, nef | 1 | 2002 | 3 | 0.010 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 5 | 0.010 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 5 | 0.010 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2002 | 4 | 0.010 |
Why?
|
| Gene Products, gag | 1 | 2002 | 11 | 0.010 |
Why?
|
| HIV Antigens | 1 | 2002 | 9 | 0.010 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2002 | 16 | 0.010 |
Why?
|
| Mental Health Services | 1 | 2005 | 199 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1987 | 848 | 0.010 |
Why?
|
| Life Style | 1 | 2005 | 338 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2002 | 38 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2002 | 66 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1985 | 426 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 489 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 951 | 0.010 |
Why?
|
| United States | 1 | 1995 | 7335 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 710 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 378 | 0.010 |
Why?
|
| Camptothecin | 1 | 2001 | 39 | 0.010 |
Why?
|
| Diet | 1 | 2005 | 513 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1174 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2001 | 83 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 307 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 508 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 370 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 1341 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1663 | 0.010 |
Why?
|
| Peptides | 1 | 2002 | 455 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 1849 | 0.010 |
Why?
|
| Adolescent | 1 | 1985 | 8903 | 0.010 |
Why?
|